Litcius/Paper detail

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, Mikhail Dvorkin, Andreia Cristina de Melo, Yaroslav Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, Marina Nechaeva, Domenica Lorusso, Giovanni Scambia, David Cibula, Róbert Póka, Ana Oaknin, Tamar Safra, Beata Mackowiak-Matejczyk, Ling Ma, Daleen Thomas, Kevin K Lin, Karen McLachlan, Sandra Goble, Amit M Oza

2022The Lancet Oncology143 citationsDOI

Topics & Concepts

MedicineCancer researchOvarian cancerChemotherapyMutationOncologyInternal medicineCancerPhases of clinical researchPoly ADP ribose polymeraseClinical trialBRCA2 ProteinOlaparibBRCA mutationTumor suppressor genePhase (matter)Chemotherapy regimenPARP inhibitorPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentBRCA gene mutations in cancer
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial | Litcius